PhaseRx, Inc. (NASDAQ: PZRX), a Seattle-based biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, has filed a chapter 11 petition before the United States Bankruptcy Court for the District of Delaware (Case No. 17-12890). The case has been assigned to the Honorable Christopher S. Sontchi. The petition indicates assets of $4.1 million and liabilities of $5.6 million. Donlin Recano will serve as the claims agent. The company has issued a press release regarding its reorganization.